Thymic carcinoma is a high-grade malignant epithelial tumor of the thymus that, unlike thymoma, demonstrates significant cytological atypia and invasive behavior. It accounts for 15-20% of all thymic epithelial tumors. Peak incidence is between ages 50-60 with a slight male predominance. Unlike thymoma, myasthenia gravis association is rare (3-5%). Histologically, squamous cell carcinoma is the most common subtype; other subtypes include lymphoepithelioma-like, basaloid, mucinous, and sarcomatoid variants. Most cases present at locally advanced or metastatic stage at diagnosis. Five-year survival ranges from 30-60% and is significantly worse than thymoma.
Age Range
40-70
Peak Age
55
Gender
Male predominant
Prevalence
Rare
Thymic carcinoma originates from thymic epithelial cells but, unlike thymoma, demonstrates significant cytological atypia, high mitotic activity, and invasive growth pattern. Tumor cells have largely lost the differentiation characteristics of normal thymic epithelium. In the squamous cell subtype, keratinization and intercellular bridges are seen. Genetic analyses may reveal TP53 mutation, KIT (CD117) overexpression, and EGFR mutations — KIT positivity is found in 70-80% of cases and is important for targeted therapy. The aggressive biology of the tumor is reflected in imaging as irregular borders, prominent vascular/mediastinal invasion, and lymphatic/hematogenous metastasis. Unlike lymphoma and germ cell tumors, thymic carcinoma shows more necrosis and cystic degeneration.
The triad of an irregularly marginated, heterogeneous, necrotic mass in the anterior mediastinum with mediastinal lymphadenopathy and vascular invasion (SVC syndrome) is highly specific for thymic carcinoma. Lymphadenopathy and hematogenous metastasis are rare in thymoma.
Irregularly marginated, heterogeneous density mass in the anterior mediastinum. Solid component shows soft tissue density (40-60 HU) on non-contrast CT while necrotic areas appear hypodense. Calcification may be more frequent and coarser than in thymoma. The tumor is usually large (>5 cm) and invades adjacent structures. Pleural or pericardial effusion may accompany.
Report Sentence
An irregularly marginated, heterogeneous density mass with necrotic areas showing aggressive morphology is seen in the anterior mediastinum, suggesting thymic carcinoma.
Shows markedly heterogeneous enhancement on contrast-enhanced CT. Solid component enhances intensely while large necrotic areas show no enhancement. Vascular invasion (superior vena cava syndrome, brachiocephalic vein occlusion), pericardial invasion, and extension into adjacent lung parenchyma should be evaluated. Mediastinal lymphadenopathy is common and important in differential from thymoma.
Report Sentence
The mass demonstrates markedly heterogeneous enhancement with large necrotic areas and vascular involvement on contrast-enhanced series, consistent with thymic carcinoma.
Mediastinal and supraclavicular lymphadenopathy is common in thymic carcinoma (30-50%) and is an important differential criterion from thymoma (lymphatic spread is rare in thymoma). Lymph nodes typically show heterogeneous enhancement and central necrosis. Paratracheal, aortopulmonary window, and subcarinal stations are the most commonly involved regions.
Report Sentence
Pathological lymphadenopathy with central necrosis is seen in mediastinal and supraclavicular regions, a finding more consistent with thymic carcinoma than thymoma.
Shows heterogeneous signal pattern on T2-weighted images. Solid component demonstrates intermediate to high signal, necrotic areas are markedly hyperintense, and fibrous areas show hypointense signal. More pronounced heterogeneity and larger necrotic areas are typical compared to thymoma. Vascular invasion can be evaluated as loss of flow void on T2.
Report Sentence
The mass shows markedly heterogeneous signal on T2-weighted sequences with hyperintense necrotic areas and intermediate signal in solid components.
Solid component shows marked diffusion restriction on DWI — lower ADC values compared to thymoma are characteristic. ADC values are generally <1.0 × 10⁻³ mm²/s. This finding can help differentiate thymic carcinoma from thymoma. Necrotic areas do not show diffusion restriction.
Report Sentence
Marked diffusion restriction with low ADC values is observed in the solid component on DWI, more consistent with thymic carcinoma than thymoma.
Shows markedly high FDG uptake on FDG PET-CT (SUVmax typically >7, often >10). Significantly higher uptake compared to thymoma is one of the most important differential features of thymic carcinoma. PET-CT is critical for distant metastasis screening and treatment response assessment. Bone, lung, and liver metastases may be detected.
Report Sentence
The anterior mediastinal mass shows markedly high FDG uptake on PET-CT (SUVmax: ...); this high metabolic activity is consistent with thymic carcinoma.
Criteria
Most common subtype (70-80%). Shows keratinization and intercellular bridges.
Distinct Features
Heterogeneously enhancing, necrotic solid mass; calcification common
Criteria
May be EBV-related. Undifferentiated carcinoma with intense lymphocytic infiltration. Better prognosis.
Distinct Features
More homogeneous enhancement, lymphoma-like appearance, younger age
Criteria
Rare subtype showing basal cell morphology. Similar to cutaneous basal cell carcinoma.
Distinct Features
Solid, homogeneously enhancing mass; necrosis less frequent
Criteria
Most aggressive subtype. Spindle cell morphology, prominent necrosis, high mitotic activity.
Distinct Features
Markedly heterogeneous, extensive necrotic areas, rapid growth, worst prognosis
Distinguishing Feature
Thymoma is typically well-defined, homogeneously enhancing, and without lymphadenopathy. Thymic carcinoma has irregular borders, heterogeneous enhancement, and common lymphadenopathy. FDG uptake is markedly higher in thymic carcinoma.
Distinguishing Feature
Lymphoma typically occurs in younger age (20-30), accompanied by B symptoms, with widespread lymphadenopathy. Thymic carcinoma presents as a localized invasive mass. Biopsy and immunohistochemistry are definitive.
Distinguishing Feature
Non-seminomatous germ cell tumors occur in young males (20-35) with elevated AFP and β-hCG. Tumor markers are usually normal in thymic carcinoma. Fat and calcification components may be present in germ cell tumors.
Distinguishing Feature
Seminoma appears as a large homogeneously enhancing mass with less necrosis. Thymic carcinoma is more heterogeneous and necrotic. β-hCG may be mildly elevated in seminoma, AFP is normal.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
3-monthThymic carcinoma treatment requires a multidisciplinary approach. Complete surgical resection plus adjuvant chemoradiation is performed in resectable cases. In unresectable cases, neoadjuvant chemotherapy (cisplatin-based) followed by surgical reassessment is done. Tyrosine kinase inhibitors such as sunitinib may be considered in KIT (CD117)-positive cases. Anti-PD-1 immunotherapy (pembrolizumab) has shown response in advanced cases. CT follow-up every 3-6 months is recommended.
Thymic carcinoma is an aggressive tumor treated with surgery, chemotherapy and radiotherapy. Prognosis is significantly worse than thymoma. Best survival rates are achieved when complete resection is possible. Distant metastasis may develop (lung, bone, liver).